Technical Specifications: Synonyms:
blood glucose monitoring is recommended [4]), injection-site reactions, and a theoretical risk of localized tissue overgrowth with chronic high-dose use
5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin Patients receiving BYDUREON BCISE in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia [see Adverse Reactions (6.1) and Drug Interactions (7)]
Some people run longer cycles (1620 weeks) without issues
The goal here is no longer rapid replenishment but steady upkeep
Bailey CR, Ahuja M, Bartholomew K, Bew S, Forbes L, Lipp A et al (2019) Guidelines for day-case surgery 2019: Guidelines from the Association of Anaesthetists and the British Association of Day Surgery